Back | Next |
home / stock / ovid / ovid message board
Subject | By | Source | When |
---|---|---|---|
Thats good enough for me . | FROZENFLAME | investorshub | 12/02/2020 10:48:33 PM |
Thats good enough for me . | FROZENFLAME | investorshub | 12/02/2020 10:48:33 PM |
Just like $BCLI. you will get a 20% | Market_scab | investorshub | 12/02/2020 10:40:23 PM |
Just like $BCLI. you will get a 20% | Market_scab | investorshub | 12/02/2020 10:40:23 PM |
way oversold. They are not a one trick pony | Market_scab | investorshub | 12/02/2020 10:39:32 PM |
way oversold. They are not a one trick pony | Market_scab | investorshub | 12/02/2020 10:39:32 PM |
$OVID Im in should have a nice bounce | FROZENFLAME | investorshub | 12/02/2020 3:48:36 PM |
$OVID Im in should have a nice bounce | FROZENFLAME | investorshub | 12/02/2020 3:48:36 PM |
big dip in ah's | saj | investorshub | 12/02/2020 12:04:30 AM |
big dip in ah's | saj | investorshub | 12/02/2020 12:04:30 AM |
3.28 in ah's | saj | investorshub | 12/02/2020 12:01:22 AM |
3.28 in ah's | saj | investorshub | 12/02/2020 12:01:22 AM |
This could turn out to be | Munchy | investorshub | 09/21/2020 10:51:31 AM |
This could turn out to be | Munchy | investorshub | 09/21/2020 10:51:31 AM |
I managed to get 500 shares | Munchy | investorshub | 09/17/2020 2:02:08 PM |
I managed to get 500 shares | Munchy | investorshub | 09/17/2020 2:02:08 PM |
I'll try to buy | Munchy | investorshub | 09/17/2020 1:21:51 PM |
I'll try to buy | Munchy | investorshub | 09/17/2020 1:21:51 PM |
What can we expect from the | Munchy | investorshub | 09/16/2020 7:56:24 PM |
What can we expect from the | Munchy | investorshub | 09/16/2020 7:56:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...